Pharmacyclics Grabs Another $50M In Milestones From J&J
This article was originally published in The Pink Sheet Daily
Executive Summary
The Sunnyvale-based biotech has received $100 million in milestone payments from its Big Pharma partner for a mid/late stage oncology drug that could be best-in-class.